Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

NCT06499857 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can help reduce atrial fibrillation events in adults who are overweight or obese.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 200 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2025-04 · est. completion 2028-06

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT06499857 ↗

Description as written by the study sponsor.

The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.

Treatments tested

Semaglutide Drug

3ml pen-injector containing semaglutide 3.0mg/ml solution for subcutaneous use.
Placebo Drug

3ml pen-injector containing placebo solution for subcutaneous use.

Main thing measured	Time to first AF event detected by routine outpatient monitoring
Sponsor	University of Chicago
Conditions studied	Overweight or Obesity, Atrial Fibrillation
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06499857 ↗